3
Announcements
Trials
Browse
Landscape
Status
Enrolling by invitation
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Lymphoid
1
Genitourinary
1
Conditions
Prostatic Neoplasms
1
Lymphoma, B-Cell
1
Leukemia, Myeloid, Acute
1
Leukemia, Lymphocytic, Chronic, B-Cell
1
Hematologic Neoplasms
1
Interventions
Blood Specimen Collection
53
Surveys and Questionnaires
49
Specimen Handling
29
Observation
15
Radiotherapy
14
Magnetic Resonance Spectroscopy
12
Surgical Procedures, Operative
11
Interviews as Topic
11
Data Collection
11
Drug Therapy
9
darolutamide
8
Biopsy
8
palbociclib
7
Watchful Waiting
7
Tomography, X-Ray Computed
7
Standard of Care
7
ribociclib
6
Magnetic Resonance Imaging
6
Bevacizumab
6
trastuzumab deruxtecan
5
Ultrasonography
5
Restraint, Physical
5
Radiofrequency Ablation
5
Patient Reported Outcome Measures
5
Mental Status and Dementia Tests
5
Mastectomy, Segmental
5
Mass Screening
5
Genetic Testing
5
Breath Tests
5
enzalutamide
4
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Observational
×
Inosine Monophosphate
×
90 days
×
Clear all
NCT07474051
2026-03-16
PERSIST
AvenCell Therapeutics, Inc.
Enrolling by invitation
178 enrolled